Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Completed · Phase 1

Conditions studied: Drug Interaction Potential

In brief

This study has two parts. Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents. Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types. In Part 2, the same participants will continue to receive pexidartinib twice daily. Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Key facts

Study ID

NCT03291288

Run by

Daiichi Sankyo

People needed

32

Starts

2018-02-26

Expected to finish

2021-04-16

Last updated by the study team

2021-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is the age of majority in country of residence
• Has a diagnosis of:
• tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity or functional limitations and for whom surgery is not an option (prior pexidartinib is permitted for TGCT patients unless ineffective or not tolerated and there has been a washout period of at least 4 weeks)
• KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST), for which there is no standard systemic therapy, or
• other solid tumors (all comers) for which there is no standard systemic therapy and there is a rationale for use of pexidartinib at the Investigator's discretion
• If a female of childbearing potential, had a negative serum pregnancy test within 14 days before enrollment, or within 72 hours before enrollment where required
• Is a non-sterile male or female willing to use of one of the protocol-defined highly effective contraception methods:
• intra-uterine device (nonhormonal or hormonal)
• sexual abstinence (only if this is in line with the patient's current lifestyle)
• barrier methods (eg, condom, diaphragm) used in combination with hormonal methods associated with inhibition of ovulation
• Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at least 50 years of age, with a follicle-stimulating hormone level > 40 milli-International units per mL (mIU/mL)
• Has adequate hematologic, hepatic, and renal function as defined by the protocol
• Is able and willing to follow all study procedures
• Has provided a signed informed consent

You may not qualify if…

• Is pregnant or breastfeeding
• Is unable to swallow oral medication
• Is unable to follow study procedures
• Is taking or has taken any medications or therapies outside of protocol-defined parameters
• Has any disease or condition that, per protocol or in the opinion of the investigator, might affect:
• safety and well-being of the participant or offspring
• safety of study staff
• analysis of results

Where it is running

• HonorHealth — Scottsdale, Arizona, United States
• University of Arizona — Tucson, Arizona, United States
• Stanford University — Palo Alto, California, United States
• University of Kansas Cancer Center — Westwood, Kansas, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Karmanos Cancer Center — Detroit, Michigan, United States
• Northwell Health — Lake Success, New York, United States
• Mary Crowley Cancer Research — Dallas, Texas, United States
• Leids Universitair Medisch Centrum — Leiden, Netherlands
• Christchurch Hospital NZ — Christchurch, New Zealand
• National Taiwan University Hospital — Taipei, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.